Want to see JP:4527 full AI Analyst Report?
4527 Stock Chart & Stats
¥2524.50
-¥41.00(-1.62%)
At close: 4:00 PM EDT
¥2524.50
-¥41.00(-1.62%)
Day’s Range― - ―
52-Week Range¥2,218.50 - ¥2,862.50
Previous CloseN/A
Volume1.22M
Average Volume (3M)643.03K
Market Cap
¥554.51B
Enterprise Value¥531.68K
Total Cash (Recent Filing)¥86.82B
Total Debt (Recent Filing)¥60.24B
Price to Earnings (P/E)15.8
Beta0.45
Next Earnings
Nov 12, 2026EPS Estimate
30.81Next Dividend Ex-DateN/A
Dividend Yield1.93%
Share Statistics
EPS (TTM)151.56
Shares Outstanding236,178,310
10 Day Avg. Volume564,110
30 Day Avg. Volume643,026
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)1.80
Price to Sales (P/S)1.58
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,950.00Price Target Upside16.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)157.09
Revenue Forecast (FY)¥368.34B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year top-line expansion with sustained mid-single-digit growth and roughly 10% net margins indicates durable demand for core OTC and personal-care products. This trend supports long-term scale benefits, brand leverage, and reinvestment capacity across product lines and geographies.
Conservative Balance SheetA strengthened equity base and manageable debt ratio preserve financial flexibility for capex, M&A, or counter-cyclical moves. Consistent ROE near double digits shows capital efficiency, supporting durable investment capacity without materially raising solvency risk.
Rising Free Cash FlowMaterial FCF growth and strong coverage of earnings bolster self-funded growth, payout capacity, and balance-sheet repair. Reliable cash generation supports sustained R&D, marketing, and international expansion without heavy reliance on external financing.
Bears Say
Margin Compression TrendA multi-year decline in core profitability margins signals structural cost pressure or adverse mix shifts that can erode long-term free cash flow and returns. If persistent, this reduces funding for innovation and weakens resilience to competitive pricing or input-cost shocks.
Step-up In DebtA marked increase in absolute debt, even at modest leverage ratios, lowers financial optionality and increases sensitivity to interest costs. This constrains ability to pursue opportunistic investments and raises refinancing risk if macro conditions tighten over the medium term.
Weak OCF Conversion And Uneven FCFLow operating cash conversion and volatile FCF imply working-capital swings or timing effects that hinder predictability of cash available for reinvestment or payouts. Structural variability complicates planning for capex, M&A, and consistent shareholder returns over time.
Rohto Pharmaceutical Co News
4527 FAQ
What was Rohto Pharmaceutical Co Ltd’s price range in the past 12 months?
Rohto Pharmaceutical Co Ltd lowest stock price was ¥2218.50 and its highest was ¥2862.50 in the past 12 months.
What is Rohto Pharmaceutical Co Ltd’s market cap?
Rohto Pharmaceutical Co Ltd’s market cap is ¥554.51B.
When is Rohto Pharmaceutical Co Ltd’s upcoming earnings report date?
Rohto Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 12, 2026 which is in 94 days.
How were Rohto Pharmaceutical Co Ltd’s earnings last quarter?
Rohto Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥47.14 earnings per share for the quarter, beating the consensus estimate of ¥39.86 by ¥7.28.
Is Rohto Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Rohto Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Rohto Pharmaceutical Co Ltd pay dividends?
Rohto Pharmaceutical Co Ltd pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 1.93%. See more information on Rohto Pharmaceutical Co Ltd dividends here
What is Rohto Pharmaceutical Co Ltd’s EPS estimate?
Rohto Pharmaceutical Co Ltd’s EPS estimate is 30.81.
How many shares outstanding does Rohto Pharmaceutical Co Ltd have?
Rohto Pharmaceutical Co Ltd has 236,178,310 shares outstanding.
What happened to Rohto Pharmaceutical Co Ltd’s price movement after its last earnings report?
Rohto Pharmaceutical Co Ltd reported an EPS of ¥47.14 in its last earnings report, beating expectations of ¥39.86. Following the earnings report the stock price went up 2.472%.
Which hedge fund is a major shareholder of Rohto Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4527
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rohto Pharmaceutical Co Ltd
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
4527 Stock 12 Month Forecast
Average Price Target
¥2,950.00
▲(16.85% Upside)